酶性清创在大于15%体表面积烧伤中的安全性
本研究回顾性分析59例部分至全层烧伤患者,比较常规使用(<15%TBSA)与超说明书使用(一次清创>15%TBSA)菠萝蛋白酶酶性清创的安全性。结果显示两组在血流动力学、炎症指标、电解质及严重不良事件方面无显著差异,但超说明书组生存率显著低于常规组(70% vs 100%,p=0.004)。
要点
- 酶性清创一次处理>15%TBSA未观察到血流动力学不稳定或电解质紊乱。
- 超说明书组生存率70%,显著低于常规组100%(p=0.004)。
- 两组炎症指标(白细胞、CRP、PCT、乳酸)及儿茶酚胺使用无差异。
核心结论
- 菠萝蛋白酶酶性清创在大于15%TBSA烧伤中未出现预期或非预期副作用,初步提示潜在安全性。
研究设计与样本
- 单中心回顾性研究,2017年1月至2018年12月共纳入59例部分至全层烧伤患者。
主要发现
- 常规组49例中位应用面积6%TBSA(IQR 2.5-9.5),超说明书组10例中位应用面积18%TBSA(IQR 15-19)。
- 两组血压、体温、血流动力学稳定性、儿茶酚胺使用及严重不良事件均无显著差异。
- 两组白细胞计数、CRP、PCT、乳酸及钠、钾、氯、磷酸盐水平均无差异,无电解质转移证据。
- 常规组生存49/49例(100%),超说明书组生存7/10例(70%),差异有统计学意义(p=0.004)。
临床怎么用
- 对于大于15%TBSA的烧伤,一次酶性清创在密切监测下可能安全,但需注意生存率差异。
局限性
- 回顾性单中心设计,超说明书组样本量小(10例),结果仅为初步证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Bromelain-based enzymatic debridement has emerged as an alternative to surgical eschar removal. Indications include partial thickness, mixed pattern, and full-thickness burns. Enzymatic debridement has been approved by the European Medicines Agency for treating burn wounds affecting <15% total body surface area (TBSA). Data and evidence for the treatment of areas >15% TBSA in one session is scarce. The aim of this retrospective study was to retrospectively analyze off-label use of enzymatic debridement in a single burn center for large TBSA burns. METHODS: Between 01/2017 and 12/2018, 59 patients with partial- to full-thickness burns underwent enzymatic debridement in a single center study. Patients were categorized into two groups: the regular use group with a treated area less than 15% TBSA and the off-label group (OG) with larger TBSA debrided in one session. Treatment was evaluated for systemic inflammatory reaction, bleeding, hemodynamic instability and electrolyte shifts. RESULTS: In total, 49 patients were treated in the regular use group with a median application area of 6% (IQR 2.5-9.5) and 10 patients were treated in the off-label group with a median application area of 18% (IQR 15-19) TBSA. We found no significant differences regarding blood pressure, body temperature or hemodynamic stability during and after enzymatic debridement. No treatment-related serious adverse events were observed in either group. Catecholamine use was similar in both groups. No differences in leukocyte counts, CRP, PCT and lactate prior to application and during the following three days were observed. Sodium, potassium, chloride and phosphate levels did not differ. We found no evidence of an electrolyte shift. Survival was 49 of 49 patients (100%) in the RG and 7 of 10 patients (70%) in the OG (p = 0.004). CONCLUSION: Enzymatic debridement did not result in any expected or unexpected side effects in the patient groups investigated. These preliminary results indicate the potential safety of bromelain-based enzymatic debridementin the treatment of burns greater than 15% TBSA.
引用
- Hofmaenner DA, Steiger P, Schuepbach RA, et al. Safety of enzymatic debridement in extensive burns larger than 15% total body surface area. Burns. 2020. PMID: 33143989. doi:10.1016/j.burns.2020.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。